Both cetuximab (Erbitux) and erlotinib (Tarceva) inhibit the epidermal growth factor receptor (EGFR) and the assumption has been that once a patient progresses on one EGFR inhibitor they will not respond to another EGFR inhibitor. The new data suggests that may not be the case.
"Just because a patient received and progressed on one EGFR inhibitor doesn't necessarily mean they will not derive clinical benefit from another one," says Hossein Borghaei, D.O., medical oncologist at Fox Chase. "And for patients who don't have a lot of treatment options, we think this is a good thing. It gives them one more drug to try when their disease is progressing."
To find out if patients whose disease is no longer controlled by cetuximab can respond to erlotinib, Borghaei and colleagues examined the treatment and clinical outcomes for a subgroup of patients who had participated in a Fox Chase clinical trial that tested a combination of carboplatin, paclitaxel and cetuximab as first-line treatment for advanced non-small cell lung cancer. Out of 53 patients who had participated in that trial, the investigators identified 15 individuals who had received erlotinib during subsequent therapy.
Of those 15 patients who received erlotinib, three remain on erlotinib. For the 12 patients who are no longer on erlotinib, the median duration of erlotinib therapy was 63 days, with a range from 36 to 222 days. The three patients remaining on therapy have been on the drug for 41, 238, and 459 days. The median progression-free survival time on erlotinib was 2.5 months for all 15 patients.
"It appears that some patients can enjoy durable disease control on erlotinib after progressing on cetuximab," Borghaei says. He cautions, however, that these data come from a subset analysis and are retrospective, so they are not conclusive, but are only hypothesis generating.
Although erlotinib is approved for use in patients with non-small cell lung cancer and cetuximab has been studied in this setting for several years, this is the first formal analysis to show that the drugs can be used in sequence. The tumor characteristics that predict clinical benefit from erlotinib after progression on a cetuximab-containing regimen is yet to be elucidated, but that is an area Dr. Borghaei would like to address in future studies.
Co-authors on the study are Karen Ruth, MS, Holly Tuttle, RN, MSN, AOCN, Roger Cohen, MD, and George Simon, MD, from Fox Chase Cancer Center, and Corey Langer, MD, from the University of Pennsylvania, Abramson Cancer Center.
Fox Chase Cancer Center is one of the leading cancer research and treatments centers in the United States. Founded in 1904 in Philadelphia as one of the nation's first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center's nursing program has received the Magnet status for excellence three consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, visit Fox Chase's web site at www.fccc.edu or call 1-888-FOX-CHASE or 1-888-369-2427.
Diana Quattrone | EurekAlert!
The Great Unknown: Risk-Taking Behavior in Adolescents
19.01.2017 | Max-Planck-Institut für Bildungsforschung
A sudden drop in outdoor temperature increases the risk of respiratory infections
11.01.2017 | University of Gothenburg
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences